Miniaturized Drug Sensitivity and Resistance Test on Patient-Derived Cells Using Droplet-Microarray. (June 2021)

• Record Type: Journal Article
• Authors: Popova, Anna A.; Dietrich, Sascha; Huber, Wolfgang; Reischl, Markus; Peravali, Ravindra; Levkin, Pavel A.
• Is Part Of: SLAS technology. Volume 26:Number 3(2021)
• Page Start: 274
• Page End: 286
• Publication Date: 2021-06
• Subjects: drug sensitivity and resistance test (DSRT) -- Droplet-Microarray -- drug screening -- primary cells -- superhydrophobicity -- personalized medicine; Medical laboratory technology -- Periodicals; Laboratories -- Equipment and supplies -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.075
• DOI: 10.1177/2472630320934432
• Languages: English
• ISSNs: 2472-6303

Abstract

Testing the sensitivity of patient-derived tumor cells ex vivo can potentially help determining the appropriate treatment for each patient and spot the development of resistance to a given therapy. The number of cells obtainable from a biopsy is, however, often insufficient for performing ex vivo tests in conventional microtiter plates. Here, we introduce a novel Droplet-Microarray platform based on a hydrophilic-superhydrophobic patterned surface that enables screenings using only 100 cells and 30 picomoles of a drug per individual nanoliter-sized droplet. We demonstrate that the dose–response of as few as 100 primary patient-derived chronic lymphocytic leukemia (CLL) cells to anticancer compounds on the Droplet-Microarray platform resembles the dose–response obtained in 384-well plates requiring 20, 000 tumor cells per experiment. The extremely miniaturized Droplet-Microarray platform thus carries great potential for ex vivo drug sensitivity and resistance tests on patient-derived tumor cells and potentially for implementing such tests in medical practice of precision medicine.